B
ACHN

Baird’s Achillion Pharmaceuticals ACHN Stock Holding History

Baird’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-63,916
Closed -$210K – 1204
2014
Q1 		$210K Buy
63,916
+106
+0.2% +$371 ﹤0.01% 1056
2013
Q4 		$212K Buy
63,810
+32,282
+102% +$93.7K ﹤0.01% 1054
2013
Q3 		$95K Buy
31,528
+11,953
+61% +$81.9K ﹤0.01% 1053
2013
Q2 		$160K Buy
+19,575
New +$149K ﹤0.01% 1013

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Baird's ACHN Position: Q2 2014 in Review

Baird sold out of Achillion Pharmaceuticals (ACHN) in Q2 2014, closing a stake of 63,916 shares — an estimated $210K sold.

Baird first reported a position in ACHN in Q2 2013 and held it in 4 quarters. The position peaked at $212K in Q4 2013. 115 funds tracked by Wall St. Rank hold ACHN as of Q2 2014.

  • Baird reported no remaining Achillion Pharmaceuticals position as of Q2 2014 after selling out during the quarter.
  • Baird sold 63,916 Achillion Pharmaceuticals shares in Q2 2014, an estimated $210K.
  • Baird first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 4 quarters.
  • Baird's Achillion Pharmaceuticals position peaked at $212K in Q4 2013.
  • 115 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2014.

Based on Baird's 13F filing for Q2 2014, filed 8 Aug 2014.